Clinical Trials Logo

Esophageal Neoplasms clinical trials

View clinical trials related to Esophageal Neoplasms.

Filter by:

NCT ID: NCT03961945 Recruiting - Barrett Esophagus Clinical Trials

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.

NCT ID: NCT03948100 Recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

Start date: December 20, 2018
Phase: N/A
Study type: Interventional

This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal cancer undergoing radiotherapy and their caregivers. Dyadic yoga intervention may help to improve physical function, fatigue, sleep difficulties, depressive symptoms, and overall quality of life for patients with non-small cell lung cancer and/or their caregivers.

NCT ID: NCT03946969 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the safety and efficacy of sintilimab combined with platinum-based chemotherapy in neoadjuvant treatment of potentially resectable esophageal cancer.

NCT ID: NCT03941626 Recruiting - Gastric Cancer Clinical Trials

Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

NCT ID: NCT03940001 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Start date: May 1, 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.

NCT ID: NCT03937362 Recruiting - Esophageal Cancer Clinical Trials

Pre-Surgery If Needed for Oesophageal Cancer

preSINO
Start date: August 8, 2019
Phase:
Study type: Observational

Prospective, multi-centre, diagnostic cohort study investigating the accuracy of positron emission tomography with computed tomography (PET-CT), endoscopic bite-on-bite biopsies and endoscopic ultrasonography (EUS) with fine-needle aspiration (FNA) for detecting residual disease after neoadjuvant chemoradiotherapy in patients with potentially curable esophageal squamous cell carcinoma (SCC).

NCT ID: NCT03936179 Recruiting - Esophageal Cancer Clinical Trials

High Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

To assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locaregionally esophageal cancer

NCT ID: NCT03933449 Completed - Clinical trials for Esophageal Carcinoma

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Start date: December 29, 2016
Phase: Phase 3
Study type: Interventional

In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed after first-line standard therapy will be randomized to receive either single agent pembrolizumab or the Investigator's choice of chemotherapy with paclitaxel, docetaxel, or irinotecan. The primary extension study hypothesis is that treatment with pembrolizumab will prolong overall survival (OS) as compared to treatment with chemotherapy.

NCT ID: NCT03922230 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer

Start date: March 1, 2019
Phase:
Study type: Observational

The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by using DNA methylation detection technology. To compare the differences in genomic methylation levels between different groups, to find out the methylolation site system associated with early esophageal squamous cell carcinoma, and to verify the genes related to esophageal squamous cell carcinoma by ctDNA methylolation. Application of basicization in early screening of esophageal squamous cell carcinoma.

NCT ID: NCT03922152 Completed - Palliative Care Clinical Trials

2D-radiotherapy in Palliation of Advanced Esophageal Cancer

SHARON-2D
Start date: January 1, 2009
Phase: N/A
Study type: Interventional

The study wants to define the efficacy of a short course 2D-radiation therapy in patients with symptomatic advanced esophageal cancer.